This systematic review aimed to evaluate existing comparative studies regarding the impact of semaglutide compared to another GLP-1 RA (liraglutide and efinopegdutide) in facilitating weight reduction and safety profile in patients with obesity [5]. Here, GCG is linked to obesity disorder.